| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Clinical Affairs
1 company
Laura Damme last filed a Form 4 in February 2023, as VP, Clinical Affairs at TMDX. Laura Damme's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 5,685 shares of TMDX. The TMDX filings lean toward selling, a net 10,937 shares.
Laura Damme has 6 Form 4 filings on record from August 2019 to February 2023, all as VP, Clinical Affairs at TransMedics Group (TMDX), 2019–2023.
The 12 reported transactions were 5 option or other derivative awards, 3 option exercises, 3 open-market sales and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $666K.
The only open-market sale was 10,937 shares of TMDX at an average $60.87 on December 15, 2022, about $666K. Twelve months later TMDX was up 30%.
Shares as reported in the last Form 4 for each company; the most recent is from February 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 15, 2022 | TMDX Transmedics Group, Inc. | VP, Clinical Affairs | Sale+OE | 10,937 | $60.87 | $665,746.61 | - | +25.7% | +30.4% |